PASG PASSAGE BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, PASSAGE BIO INC reported revenue of n/a, net income of −$7.82M and diluted EPS of −$2.44; for the fiscal year ended December 2025 revenue was n/a.
PASG annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$49.3M, net income −$45.5M (margin n/a), EPS −$14.35
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$70.4M, net income −$64.8M (margin n/a), EPS −$21.04
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$108M, net income −$102M (margin n/a), EPS −$1.86
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$138M, net income −$136M (margin n/a), EPS −$2.50
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$186M, net income −$185M (margin n/a), EPS −$3.48
PASG quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$7.82M, EPS −$2.44
- Quarter ended Mar 31, 2026: revenue n/a, net income −$7.56M, EPS −$2.36
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$13.0M, EPS −$4.08
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.75M, EPS −$2.44
- Quarter ended Jun 30, 2025: revenue n/a, net income −$9.39M, EPS −$2.96
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.4M, EPS −$4.87
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.7M, EPS −$9.50
- Quarter ended Sep 30, 2024: revenue n/a, net income −$19.3M, EPS −$6.15
- Quarter ended Jun 30, 2024: revenue n/a, net income −$16.0M, EPS −$5.09
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.7M, EPS −$0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$16.8M, EPS −$0.30
- Quarter ended Sep 30, 2023: revenue n/a, net income −$27.1M, EPS −$0.49
- Quarter ended Jun 30, 2023: revenue n/a, net income −$23.9M, EPS −$0.44
- Quarter ended Mar 31, 2023: revenue n/a, net income −$34.3M, EPS −$0.63
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$27.1M, EPS −$0.49
- Quarter ended Sep 30, 2022: revenue n/a, net income −$26.7M, EPS −$0.49
- Quarter ended Jun 30, 2022: revenue n/a, net income −$39.5M, EPS −$0.73
- Quarter ended Mar 31, 2022: revenue n/a, net income −$42.8M, EPS −$0.79
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$51.2M, EPS −$0.95
- Quarter ended Sep 30, 2021: revenue n/a, net income −$46.9M, EPS −$0.87
PASG cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$31.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$48.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$78.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$118M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$127M, share buybacks n/a
PASG balance sheet
- Jun 30, 2026: cash $24.2M, total assets $25.2M, total liabilities $20.7M, shareholders' equity $4.46M
- Mar 31, 2026: cash $33.3M, total assets $36.5M, total liabilities $24.7M, shareholders' equity $11.8M
- Dec 31, 2025: cash $46.3M, total assets $62.3M, total liabilities $43.5M, shareholders' equity $18.8M
- Sep 30, 2025: cash $52.8M, total assets $74.2M, total liabilities $43.0M, shareholders' equity $31.1M
- Jun 30, 2025: cash $57.6M, total assets $79.2M, total liabilities $40.9M, shareholders' equity $38.3M
- Mar 31, 2025: cash $63.4M, total assets $86.0M, total liabilities $39.3M, shareholders' equity $46.7M
- Dec 31, 2024: cash $37.6M, total assets $102M, total liabilities $41.2M, shareholders' equity $61.3M
- Sep 30, 2024: cash $32.3M, total assets $112M, total liabilities $39.0M, shareholders' equity $72.7M
Is PASG profitable?
No. PASSAGE BIO INC lost $36.1M over the last four quarters.
What is PASG's EPS?
Diluted earnings per share over the last four quarters were −$11.32; −$2.44 in the latest quarter.